Is Octreotide Benefitial in Patients with Metastatic Gastroenteropancreatic (GEP) and Hepatobiliary Neuroendocrine Carcinoma (NEC)? Abstract #608

Introduction: Neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) and hepatobiliary (HB) tract are rare and a heterogenous group of malignancies. Octreotide showed the anti-tumor activity in well-differentiated metastatic midgut neuroendocrine tumors (NETs).
Aim(s): It has not been evaluated whether octreotide in NEC affects survival outcome or not.
Materials and methods: We analyzed 17 patients (6 ; HB- and 11 ; GEP- tract) with metastatic NEC who had been diagnosed between January 2009 and June 2012. All patients had one or more cytotoxic chemotherapy and nin had received octreotide as a single agent (n=3) or combination of cytotoxic chemotherapy (n=6) during treatment period.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Seung Kim
Authors: Kim S
Keywords: NEC, octreotide, GEP, HB

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result